1. Home
  2. SGU vs PROK Comparison

SGU vs PROK Comparison

Compare SGU & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGU

Star Group L.P.

N/A

Current Price

$13.32

Market Cap

431.4M

ML Signal

N/A

Logo ProKidney Corp.

PROK

ProKidney Corp.

N/A

Current Price

$1.05

Market Cap

359.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SGU
PROK
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
431.4M
359.4M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
SGU
PROK
Price
$13.32
$1.05
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $6.50
AVG Volume (30 Days)
21.1K
★ 1.4M
Earning Date
12-07-2026
11-12-2026
Dividend Yield
★ 5.93%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $1,784,418,000.00
$893,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.70
★ N/A
Revenue Growth
N/A
★ 1075.00
52 Week Low
$11.60
$0.87
52 Week High
$13.53
$2.65

Technical Indicators

Market Signals
Indicator
SGU
PROK
Relative Strength Index (RSI) 65.72 36.16
Support Level $12.35 $0.87
Resistance Level $13.53 $1.76
Average True Range (ATR) 0.23 0.11
MACD 0.02 0.00
Stochastic Oscillator 100.00 15.19

Price Performance

Historical Comparison
SGU
PROK

About SGU Star Group L.P.

Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: